Back to results

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge

Primary Purpose

COVID-19

Status

Completed

Phase

Not Applicable

Locations

Israel

Study Type

Interventional

Intervention

NovoTTF-100L

About this trial

This is an interventional treatment trial for COVID-19

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Age ≥ 18 years.
Hospitalized with diagnosis of COVID-19 infection per reverse transcription polymerase chain reaction (RT-PCR) within 72 hours prior to treatment start.
SpO2 ≤ 93% at sea level.
Lung involvement confirmed with chest imaging.
Able and willing to comply with all study procedures.
Female participants of childbearing age must use highly effective contraception.
All patients must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.

Exclusion Criteria:

Receipt of any experimental treatment for COVID-19 prior to or during the study.
Assisted ventilation.
Critical illness: respiratory failure defined as oxygen saturation by pulse oximetry/inspired oxygen fraction (SpO2/FiO2) ratio < 150, septic shock, and/or multiple organ dysfunction.
Significant co-morbidities at baseline as determined by the investigator:
1. Clinically significant hematological, hepatic and renal dysfunction, defined as: Neutrophil count < 1.5 x 10^9/L and platelet count < 100 x 10^9/L; bilirubin > 1.5 x upper limit of normal (ULN); aspartate aminotransferase (AST) and/or alanine transaminase (ALT) > 2.5 x ULN; and serum creatinine > 2.5 mg/dL.
2. History of significant cardiovascular disease unless the disease is well controlled. Significant cardiac disease includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class IV (unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases).
3. History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the study.
4. History of any psychiatric condition that might impair patient's ability to understand or comply with the requirements of the study or to provide consent.
Implantable electronic medical devices (e.g. pacemaker, defibrillator) in the upper torso.
Pregnancy or breast-feeding.
Known allergies to medical adhesives or hydrogel.
Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's cooperation or other unspecified reasons that, in the opinion of the Investigator or sponsor, make the subject's enrollment incompatible with study objectives.

Sites / Locations

Hadassah Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

NovoTTF-100L

Arm Description

Patients receive TTFields using the NovoTTF-100L System together with COVID-19 best standard of care

Outcomes

Primary Outcome Measures

Frequency and severity of adverse events

Secondary Outcome Measures

All-cause mortality

The proportion of participants who died by study Day 29.

Incidence of intensive care unit admission

Incidence of non-invasive ventilation or high-flow oxygen use

Incidence of invasive ventilation

Incidence of extracorporeal membrane oxygenation

Patient inflammatory status

Inflammatory status measured as the difference in C reactive protein (CRP), D-dimer and ferritin blood levels from baseline on days 3, 8 and 11 until discharge.

Duration of hospitalization

Time to recovery

Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities.

Clinical status at day 8, 15, 22, 29

Clinical status according to ordinal scale. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.

Full Information

NCT ID

NCT04953234

First Posted

July 4, 2021

Last Updated

July 4, 2021

Sponsor

NovoCure GmbH

1. Study Identification

Unique Protocol Identification Number

NCT04953234

Brief Title

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge

Official Title

A Pilot, Open-Label Study of NovoTTF-100L (TTFields, 150Hz) in Hospitalized Patients With COVID-19 and Continued Treatment After Hospitalization

Study Type

Interventional

2. Study Status

Record Verification Date

July 2021

Overall Recruitment Status

Completed

Study Start Date

February 23, 2021 (Actual)

Primary Completion Date

April 26, 2021 (Actual)

Study Completion Date

April 26, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

NovoCure GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

5. Study Description

Brief Summary

The study is a prospective, pilot study aimed to test the safety of Tumor Treating Fields (TTFields) concomitant with best standard of care, for the treatment of hospitalized COVID-19 patients and continued treatment after hospitalization. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields) to the region of the organ to be treated, by means of surface, insulated electrode arrays.

Detailed Description

PAST PRE-CLINICAL AND CLINICAL EXPERIENCE: Tumor Treating Fields (TTFields) are a non-invasive, regional antimitotic treatment modality with minimal toxicity which have been approved for the treatment of recurrent and newly diagnosed glioblastoma (GBM) by the Food and Drug Administration (FDA) in the United States and have obtained a CE mark in Europe for the same indications. TTFields concomitant with chemotherapy were also approved for malignant pleural mesothelioma under FDA's humanitarian device exemption. Cell culture study demonstrated that TTFields can significantly reduce corona virus infection and replication in human lung cells. DESCRIPTION OF THE STUDY: All patients included in this study are patients who are hospitalized due to COVID-19 disease. In addition, all patients must meet all eligibility criteria. Eligible patients will be enrolled to the study and will receive COVID-19 best standard of care treatment concomitant with TTFields using the NovoTTF-100L System. The patients will be treated continuously with the device until discharge from the hospital and until there are no limitations on activities. SCIENTIFIC BACKGROUND: Electric fields exert forces on electric charges similar to the way a magnet exerts forces on metallic particles within a magnetic field. These forces cause movement and rotation of electrically charged biological building blocks, much like the alignment of metallic particles seen along the lines of force radiating outwards from a magnet. Electric fields can also cause muscles to twitch and if strong enough may heat tissues. TTFields are alternating electric fields of low intensity. This means that they change their direction repetitively many times a second. Since they change direction very rapidly (150 thousand times a second), they do not cause muscles to twitch, nor do they have any effects on other electrically activated tissues in the body (brain, nerves and heart). Since the intensities of TTFields in the body are very low, they do not cause heating. The breakthrough finding made by Novocure was that alternating fields of very low intensity, now termed TTFields (Tumor Treating Fields), attenuate SARS-CoV-2 virus infection and replication. TTFields can be directed to a certain part of the body, leaving sensitive areas out of their reach. In conclusion, TTFields hold the promise of serving as a brand new treatment for COVID-19 disease with very few side effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

COVID-19

7. Study Design

Primary Purpose

Treatment

Study Phase

Not Applicable

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

10 (Actual)

8. Arms, Groups, and Interventions

Arm Title

NovoTTF-100L

Arm Type

Experimental

Arm Description

Patients receive TTFields using the NovoTTF-100L System together with COVID-19 best standard of care

Intervention Type

Device

Intervention Name(s)

NovoTTF-100L

Other Intervention Name(s)

TTFields

Intervention Description

Patients receive continuous TTFields treatment using the NovoTTF-100L device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.

Primary Outcome Measure Information:

Title

Frequency and severity of adverse events

Time Frame

2 months

Secondary Outcome Measure Information:

Title

All-cause mortality

Description

The proportion of participants who died by study Day 29.

Time Frame

Day 1 through Day 29

Title

Incidence of intensive care unit admission

Time Frame

Day 1 through Day 29

Title

Incidence of non-invasive ventilation or high-flow oxygen use

Time Frame

Day 1 through Day 29

Title

Incidence of invasive ventilation

Time Frame

Day 1 through Day 29

Title

Incidence of extracorporeal membrane oxygenation

Time Frame

Day 1 through Day 29

Title

Patient inflammatory status

Description

Inflammatory status measured as the difference in C reactive protein (CRP), D-dimer and ferritin blood levels from baseline on days 3, 8 and 11 until discharge.

Time Frame

Day 3, 8, and 11

Title

Duration of hospitalization

Time Frame

Day 1 through Day 29

Title

Time to recovery

Description

Time Frame

Day 1 through Day 29

Title

Clinical status at day 8, 15, 22, 29

Description

Time Frame

Day 8, 15, 22, and 29

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Age ≥ 18 years. Hospitalized with diagnosis of COVID-19 infection per reverse transcription polymerase chain reaction (RT-PCR) within 72 hours prior to treatment start. SpO2 ≤ 93% at sea level. Lung involvement confirmed with chest imaging. Able and willing to comply with all study procedures. Female participants of childbearing age must use highly effective contraception. All patients must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted. Exclusion Criteria: Receipt of any experimental treatment for COVID-19 prior to or during the study. Assisted ventilation. Critical illness: respiratory failure defined as oxygen saturation by pulse oximetry/inspired oxygen fraction (SpO2/FiO2) ratio < 150, septic shock, and/or multiple organ dysfunction. Significant co-morbidities at baseline as determined by the investigator: Clinically significant hematological, hepatic and renal dysfunction, defined as: Neutrophil count < 1.5 x 10^9/L and platelet count < 100 x 10^9/L; bilirubin > 1.5 x upper limit of normal (ULN); aspartate aminotransferase (AST) and/or alanine transaminase (ALT) > 2.5 x ULN; and serum creatinine > 2.5 mg/dL. History of significant cardiovascular disease unless the disease is well controlled. Significant cardiac disease includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class IV (unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases). History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the study. History of any psychiatric condition that might impair patient's ability to understand or comply with the requirements of the study or to provide consent. Implantable electronic medical devices (e.g. pacemaker, defibrillator) in the upper torso. Pregnancy or breast-feeding. Known allergies to medical adhesives or hydrogel. Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's cooperation or other unspecified reasons that, in the opinion of the Investigator or sponsor, make the subject's enrollment incompatible with study objectives.

Facility Information:

Facility Name

Hadassah Medical Center

City

Jerusalem

Country

Israel

12. IPD Sharing Statement

Plan to Share IPD

Undecided

Learn more about this trial

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge

We'll reach out to this number within 24 hrs